These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20361465)

  • 21. Immunologic systemic effect of neoadjuvant chemotherapy requires investigation before tumor-associated lymphocytes can be introduced in breast cancer treatment algorithm.
    Bellati F; Napoletano C; Gasparri ML; Panici PB; Nuti M
    J Clin Oncol; 2010 Sep; 28(27):e471-2; author reply e473. PubMed ID: 20585098
    [No Abstract]   [Full Text] [Related]  

  • 22. Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
    Ellis MJ
    J Clin Oncol; 2005 Aug; 23(22):4842-4. PubMed ID: 15998901
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of neoadjuvant chemotherapy in the management of primary breast cancer.
    Aigner J; Schneeweiss A; Sohn C; Marmé F
    Minerva Ginecol; 2011 Jun; 63(3):261-74. PubMed ID: 21654611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Certain aspects of neoadjuvant therapy of locally advanced breast cancer].
    Voznyĭ EK; Gurov SN; Dobrovol'skaia NIu
    Vopr Onkol; 2001; 47(6):690-4. PubMed ID: 11826490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.
    Loo CE; Straver ME; Rodenhuis S; Muller SH; Wesseling J; Vrancken Peeters MJ; Gilhuijs KG
    J Clin Oncol; 2011 Feb; 29(6):660-6. PubMed ID: 21220595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer.
    Davidson NE; Morrow M
    J Natl Cancer Inst; 2005 Feb; 97(3):159-61. PubMed ID: 15687353
    [No Abstract]   [Full Text] [Related]  

  • 28. Can diffusion-weighted MR imaging be used as a biomarker for predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer?
    Iacconi C; Giannelli M
    Radiology; 2011 Apr; 259(1):303-4. PubMed ID: 21436100
    [No Abstract]   [Full Text] [Related]  

  • 29. The Neoadjuvant Model and Complete Pathologic Response in Breast Cancer: All or Nothing?
    Bossuyt V; Hatzis C
    JAMA Oncol; 2016 Jun; 2(6):760-1. PubMed ID: 26914064
    [No Abstract]   [Full Text] [Related]  

  • 30. [Significance and specifics of surgical treatment in locally advanced breast cancer].
    Ostapenko V; Ostapenko A
    Vopr Onkol; 2011; 57(5):578-83. PubMed ID: 22238926
    [No Abstract]   [Full Text] [Related]  

  • 31. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with breast cancer].
    Tamaki T; Oura S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():198-201. PubMed ID: 17682157
    [No Abstract]   [Full Text] [Related]  

  • 32. Case report of bilateral inflammatory breast cancer.
    Masannat YA; Peter M; Turton P; Shaaban AM
    Eur J Cancer Care (Engl); 2010 Jul; 19(4):558-60. PubMed ID: 19708943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin as an addition to conventional chemotherapy in breast cancer.
    Grenader T; Goldberg A; Shavit L
    J Clin Oncol; 2009 Dec; 27(35):e259; author reply e260. PubMed ID: 19884518
    [No Abstract]   [Full Text] [Related]  

  • 35. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.
    Choi JH; Lim HI; Lee SK; Kim WW; Kim SM; Cho E; Ko EY; Han BK; Park YH; Ahn JS; Im YH; Lee JE; Yang JH; Nam SJ
    J Surg Oncol; 2010 Oct; 102(5):392-7. PubMed ID: 19877158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant therapy for breast cancer.
    Liu SV; Melstrom L; Yao K; Russell CA; Sener SF
    J Surg Oncol; 2010 Mar; 101(4):283-91. PubMed ID: 20187061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy for operable breast cancer.
    Green M; Hortobagyi GN
    Oncology (Williston Park); 2002 Jul; 16(7):871-84, 889; discussion 889-90, 892-4, 897-8. PubMed ID: 12164555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer.
    Donker M; Hage JJ; Woerdeman LA; Rutgers EJ; Sonke GS; Vrancken Peeters MJ
    Eur J Surg Oncol; 2012 Jan; 38(1):25-30. PubMed ID: 21963981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metformin in breast cancer: time for action.
    Goodwin PJ; Ligibel JA; Stambolic V
    J Clin Oncol; 2009 Jul; 27(20):3271-3. PubMed ID: 19487373
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.